Wolfram syndrome is an autosomal recessive disorder characterized by juvenile diabetes mellitus, diabetes insipidus, optic atrophy and a number of neurological symptoms including deafness, ataxia and peripheral neuropathy. Mitochondrial DNA deletions have been described in a few patients and a locus has been mapped to 4p16 by linkage analysis. Susceptibility to psychiatric illness is reported to be high in affected individuals and increased in heterozygous carriers in Wolfram syndrome families. We screened four candidate genes in a refined critical linkage interval covered by an unfinished genomic sequence of 600 kb. One of these genes, subsequently named wolframin, codes for a predicted transmembrane protein which was expressed in various tissues, including brain and pancreas, and carried loss-of-function mutations in both alleles in Wolfram syndrome patients.
INTRODUCTION
The first description of Wolfram syndrome (MIM 222300) is attributed to the physician D.J. Wolfram (1) , who reported four cases in 1938. The acronym DIDMOAD summarizes the most frequent findings: diabetes insipidus, diabetes mellitus, optic atrophy and deafness. The minimal criteria for diagnosis are diabetes mellitus and optic atrophy. Diabetes insipidus, sensorineuronal deafness, urinary tract atony, ataxia, peripheral neuropathy, mental retardation and psychiatric illness are additional symptoms seen in the majority of patients. Diabetes mellitus is usually the first symptom, with the age of onset in the second half of the first decade (range 1-26 years). The mean onset of optic atrophy is in the first half of the second decade (range 6 weeks to 30 years). The prevalence has been estimated to be 1/770 000 in the UK and 1/100 000 in the North American population (2, 3) . The syndrome is best described as a neurodegenerative disorder involving the central nervous system, peripheral nerves and neuroendocrine tissue. Affected siblings with unaffected parents, often consanguineous, suggests a recessive mode of inheritance (4, 5) . The similarity in phenotype between patients with Wolfram syndrome and those with certain types of respiratory chain diseases led to the investigation of mitochondrial DNA (mtDNA) mutations in Wolfram syndrome patients. Deletions in mtDNA and morphological mitochondrial abnormalities were reported in some sporadic and familial cases (6) (7) (8) . However, the mitochondrial tRNA Leu (3243) mutation (2) and deletions in the mitochondrial genome have been excluded in >20 patients (9) (10) (11) .
Linkage analysis in families with autosomal recessive Wolfram syndrome has shown significant lod scores for a locus on chromosome 4p16 between D4S432 and D4S431 (12, 13) . In two families in whom linkage has been demonstrated to this locus, multiple mtDNA deletions were found in both homozygous and heterozygous family members, suggesting a nuclear disease gene which interacts deleteriously with the mitochondrial genome (6) . Although the phenotype in Wolfram syndrome is highly variable, no distinct clinical subgroups have been described so far. Psychiatric manifestations are particularly diverse and an increased predisposition for psychiatric disorders has been proposed for heterozygous carriers (14) . We used unfinished genomic sequences from a chromosome 4 sequencing project to identify candidate genes for mutation screening in patients with Wolfram syndrome. Segregation analysis in autosomal recessive families led to a refined critical interval of 600 kb which was shown to contain at least four genes. One of them, a novel gene coding for a predicted 100 kDa transmembrane protein, harbored mutations in eight patients with Wolfram syndrome.
RESULTS

Analysis of candidate genes
We investigated DNA samples from three familial and nine sporadic patients with a clinical diagnosis of Wolfram syndrome. Minimum ascertainment criteria were juvenile diabetes mellitus and progressive optic atrophy (Table 1) . mtDNA mutations and deletions were excluded in all affected individuals. In seven index cases (families 1-7, Table 1 ), an extensive screen for mtDNA mutations has been reported, including single-stranded conformation polymorphism (SSCP) analysis of all mitochondrial ND and tRNA genes (11) . In five further cases, a deletion screen by Southern blotting of mtDNA was performed. In addition, the three primary LHON mutations (3460, 11778 and 14484) and three MELAS mutations (3243, 3271 and 3251) were not detected on screening.
We performed segregation analysis with 4p markers in three families in which at least two siblings were affected. Assuming that the disease locus in these families was linked to the reported interval between D4S432 and D4S431, we screened for single recombination events in this region. Haplotype analysis in pedigree 02 with two affected and two unaffected siblings revealed a crossover event between D4S2354 and D4S431 in an affected individual (Fig. 1) . This provisionally mapped the disease locus proximal to marker D4S2354 and led to a refined critical interval between this marker and D4S431.
The Stanford Human Genome Center constructed a BAC contig between D4S842 and D4S611, which included the markers D4S2354 and D4S431, and made unfinished sequences available electronically to all investigators (http://wwwshgc.stanford.edu/Seq ). We analyzed the DNA sequences from six BACs falling into the interval between D4S2354 and D4S431 ( Fig. 2 ). All six BAC clones harbored gaps which, given the total length of the clones, should constitute <5% of the complete genomic sequences. Assembly of the BAC sequences with the program FALCON allowed the construction of larger contigs. The contigs were ordered by the known position of genetic markers and overlapping cDNAs and ESTs. According to this assembly, the physical distance between the two flanking markers was ∼600 kb. Screening of EST and non-redundant DNA databases with BLAST, combined with the use of exon prediction programs, revealed at least four known or predicted genes in this region ( Fig.  2 ): (i) the gene for dihydropyriminidase-related protein-1 (DRP-1, GenBank accession no. D78012); (ii) the human homolog of the rat mRNA for the γ isoform of the B regulatory subunit of protein phosphatase 2A (BRg, GenBank accession no. D38261); (iii) WM3, a novel gene partially covered by ESTs detected in brain and retinal tissue and with an overall amino acid identity of 58% (similarity 74%) over 397 amino acids to the KIAA0555 protein (GenBank accession no. 3043634) of unknown function; (iv) WM1, also partially covered by ESTs, which showed no significant homology to published DNA or protein sequences. A potential fifth gene, WM4, was defined by gene prediction programs only. For this gene, at least 6 exons spread over a genomic region of 40 kb were predicted by at least two programs used. No significant homology could be retrieved in a database search with sequences encompassing WM4.
Primers were designed for a total of 36 exons belonging to the above genes, with the exception of WM4, and a mutation screen was performed by SSCP in all 12 Wolfram syndrome index patients. Aberrant migration patterns suggesting mutations in the DRP-1, BRg and WM3 genes were few and sequencing revealed intronic nucleotide substitutions, a silent mutation in exon 8 of BRg and an arginine/histidine and a proline/threonine polymorphism in exon 6 of DRP-1. In contrast, screening of WM1 resulted in a significant number of gel shifts, some of which turned out to be due to homozygous deletions in Wolfram syndrome patients. WM1 was therefore named wolframin and characterized further.
Overlapping RT-PCR and 5′-RACE was performed with adult brain tissue as template to establish the cDNA sequence of WM1. The cDNA consists of 3628 bp encompassing seven small exons and a large last exon of 2609 bp. Exons 3-5, 7 and 8 were predicted by GENSCAN (15), GRAIL (16) and GENEFINDER, exon 6 by GENSCAN and GRAIL and exon 2 by GENSCAN only. Sequence analysis of the cDNA predicted an ORF of 2670 bp. The sequences around the putative ATG translation start site (cgggccggcaggatgg) contained the -3 purine and +4 guanine residues of the Kozak consensus sequence. No in-frame stop codon was present upstream of the predicted start site. A possible promotor was predicted (TSSW program) at the beginning of the composite cDNA with a TATA box 34 bp upstream of the putative transcription start site. The 3′-UTR consisted of 797 bp with a polyadenylation signal (AATAAA) 771 bp downstream of the stop codon.
wolframin mutations
To assess the possible role of this candidate gene in Wolfram syndrome, exons 2-7 were amplified from affected individuals with primer pairs based on exon-intron boundaries (Table 2) and screened for mutations using SSCP. Exon 8 was divided into eight overlapping parts of ∼300 bp for SSCP screening. Sequencing of exons with aberrant migration patterns (Fig. 3) revealed mutations in the three familial cases and in five of the nine sporadic cases ( Table 3 ). The mutations included stop, frameshift and amino acid deletions and insertions, suggesting wolframin lossof-function mutations as the cause of Wolfram syndrome. Sequencing of aberrant bands also revealed several intronic and eight exonic polymorphisms. Six of the exonic polymorphisms are silent substitutions (PM684 C/G, PM1185 C/T, PM1500 C/T, PM2433 A/G, PM2469 C/T and PM2565 A/G). Two exonic polymorphisms are characterized by either valine or isoleucine at amino acid position 333 (PM997 A/G) and by either histidine or arginine at amino acid position 611 (PM1832 A/G).
Characterization of wolframin
The 890 amino acid wolframin protein corresponded to a predicted molecular weight of 100 kDa. BLAST and FASTA searches showed no significant homology to published DNA or protein sequences. Protein structure prediction programs (17, 18) identified a hydrophobic central domain (amino acids 330-650) comprising nine helical transmembrane segments. Both programs preferentially predicted the N-terminal hydrophilic part to lie extracytoplasmically and the C-terminal part to lie intracytoplasmically. PSORT (19) computed a probability of 65% for a localization in the plasma membrane, 26% for endoplasmatic reticulum and 4% for a mitochondrial or nuclear localization. These features suggested wolframin encodes a transmembrane protein.
Hybridization of a PCR-derived exon 8 fragment (wm1E7-2-5) against a Southern blot containing EcoRI-and PstI-digested genomic DNA revealed a single band per digest and no cross-hybridization signals. The bands corresponded to the expected EcoRI fragment of 16.4 kb and the expected PstI fragment of 4.4 kb. Probe wm1E7-2-5 was also used to hybridize a Zoo blot and specific signals were observed in mammals (data not shown). No cross-hybridization was observed with genomic DNA from Drosophila and yeast. Hybridization of the probe to a multi-tissue northern blot revealed a signal of ∼3.6 kb in all tissues (Fig. 4) . The signal was strong in heart, intermediate in brain, placenta, lung and pancreas and weak in liver, skeletal muscle and kidney. The 3.6 kb band corresponded to the length of the assembled wolframin cDNA.
Mouse homolog of wolframin
Primers derived from mouse EST sequences were used to amplify the mouse homolog of wolframin by RT-PCR. 5′-Sequences corresponding to human exons 3 and 4 and 3′-sequences corresponding to exon 8 were covered by the mouse IMAGE clones 526533 and 1152973, respectively. IMAGE clone 526533 was presumably mis-spliced and, in addition to exons 3 and 4, contained sequences corresponding to the 3′-UTR of wolframin. A sequence was amplified which corresponds to the human cDNA sequence starting at nucleotide position 316. 5′-RACE was used to amplify an additional 206 bp resulting in a composite sequence which covers the entire ORF of mouse wolframin. Human and murine sequences are highly homologous, with 83% identity at the nucleotide level and 87% at the amino acid level (Fig. 5) .
DISCUSSION
We have identified a gene mutated in patients with Wolfram syndrome by a positional cloning approach. Loss-of-function mutations on both alleles were demonstrated in five out of 12 families studied and we conclude that lack of the putative gene product (wolframin) is causative for the disease. The mutation status of a heterozygous missense mutation (Y669C), and of two homozygous in-frame mutations (1380del9 and 2164ins24) remains unclear pending functional studies. These sequence alterations were not found in 200 control chromosomes.
In one of the families (family 05) only a heterozygous stop mutation was found. No mutations in either of the two alleles were detected in three families (families 03, 10 and 11). One of these (family 03) was reported to be consanguineous. Mutations in exon 1, which was not included in the mutation screen, intronic mutations including deletions or mutations in the regulatory flanking regions of the gene could be pathogenic in these families. Non-allelic heterogeneity provides an alternative explanation (12). Wolfram syndrome is a rare autosomal recessive disorder and, accordingly, a high proportion of homozygous mutations (five out of eight) were observed, although consanguinity was recorded in only one of the five families. The mutations were distributed along the entire gene and there was no evidence for a founder mutation in the seven families. No obvious genotypephenotype relationship emerged. For example, diabetes insipidus was absent in the index patient of family 04 with a proximal frameshift mutation, but present in the index patient of family 06 with the most distal stop mutation.
This cloning project was greatly aided by the unfinished genomic sequences made available from the Stanford Human Genome Center. With no chromosomal aberration present in our panel of patient samples, gene identification relied on exon prediction and the identification of ESTs in the critical linkage interval. For refining this interval, we relied on a recombination event in a family with only two affected members. Mutation analysis in this family (family 02) has shown that there was indeed a homozygous splice site mutation present in the wolframin gene. The five genes predicted by EST clusters and exon prediction programs occupy ∼225 kb of the 600 kb refined interval. ESTs derived from the gene coding for DRP-1 (GenBank accession no. D78012) and WM3 (SHGC-25149) had already been localized to this region. The gene encoding BRg (GenBank accession no. D38261) is located tail-to-tail only 17 kb proximal of wolframin. It has been shown to be highly expressed in brain and in spinal cord (20) . The 5′-end of wolframin was not fully represented on genomic sequences. It is known from large-scale sequencing projects that promoter regions are underrepresented due to GC-rich regions at upstream regulatory sequences. According to the human/mouse synteny map, the highly homologous mouse wolframin gene should be located on mouse chromosome 5. Flanking markers include the mouse genes Msx1 and Drd5. No mouse mutants with degenerative disease map to this region.
mtDNA deletions have been excluded in peripheral leukocytes of the 12 index patients investigated in the present study. In particular, no mtDNA mutation was found in skeletal muscle from a patient with a homozygous wolframin mutation (family 08). This argues against a mechanism in which wolframin mutations trigger a pathogenic mechanism involving both the nuclear and the mitochondrial genome. Nonetheless, the clinical signs of the disease favor a disease mechanism which involves a mitochondrial protein. This reasoning gains support from the finding of mitochondrial pathology in one of the patients (family 08), in whom we found two compound heterozygous wolframin mutations. Wolframin is expressed in all tissues tested. Notably, the band observed in the skeletal muscle lane was of low intensity compared with the high intensity band seen in heart muscle. It is known that expression levels of genes coding for mitochondrial proteins do not solely reflect the number of mitochondria in a cell or tissue. Secondary structure prediction revealed the signature of a typical membrane protein: a central hydrophobic domain flanked by two hydrophilic domains. The number of helical domains crossing the membrane is predicted to be nine, positioning the N-and C-termini of wolframin on different sides of the membrane. The low score given for a mitochondrial sublocalization is explained by the absence of a typical import signal. With no significant homologies found in the databases, this defines a novel membrane protein, which may eventually provide a new means for studying neurodegenerative processes. Determination of its subcellular localization will reveal the first clues to its functional role.
The pleiotropic effects caused by wolframin mutations include a spectrum of psychiatric disorders. In three patients with mutations described in this study, psychiatric illness has been recorded. A locus for a dominant bipolar disorder has been mapped to 4p (21) . These linkage studies were repeated in other patient samples with bipolar disorder (22) . The interval defined by these studies includes markers which flank the wolframin gene. Combined with the observation that heterozygous carriers in recessive Wolfram syndrome families are predisposed to psychiatric illness, haploinsufficiency of wolframin could predispose to psychiatric illness (14) . The gene structure presented here provides the tools to test this hypothesis.
MATERIALS AND METHODS
Patients
A summary of clinical details available from 12 families with Wolfram syndrome is given in Table 1 . Histochemical analysis of a muscle biopsy in patient 13073 (family 08) was compatible with the diagnosis of ragged red fibres. The families were of German (families 3-7, 10 and 11), Turkish (families 1, 2 and 8), Yugoslavian (family 9) and Portuguese (family 12) descent.
Sequence analysis
Homology searches against the non-redundant and EST databases were performed using BLAST and FASTA. GENSCAN (15) , GRAIL (16) and GENEFINDER (C. Wilson, L. Hillier and P. Green, personal communication) were used as exon prediction programs. Genome-wide repeats were identified using the REPEATMASKER program. GENOTATOR was used to display the results of the exon predictions programs, BLAST and repeats searches (23) . Sequence alignments were performed using the Global Alignment Program (GAP) and CLUSTALW.
RT-PCR and RACE
RT-PCR was performed using 1-2 ng of human or mouse adult brain cDNA (Clontech) as templates. RACE was done using the Marathon cDNA Amplification Kit (Clontech). Primers designed from the predicted cDNA sequence were used for amplification of 0.2-2 kb products and are available on request. The probe wm1E7-2-5 was obtained with the following primer pair: wm1E7-2F, 5′-AGAACTTCCGCACCCTCAC-3′; wm1E7-5R, 5′-GTAGAGGCAGCGCATCCAG-3′.
Northern blot analysis
The multiple tissue northern blot contained 2 µg poly(A) + RNA each from heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas (Clontech). Hybridization with probe wm1E7-2-5 (see RT-PCR above) was performed in Church buffer at 65_C; washing was with 0.01× SSC at 60_C.
Mutation analysis
mtDNA deletions were screened by Southern blotting and mtDNA point mutations at positions 3460, 11778 and 14484 (LHON mutations) and 3243, 3271 and 3251 (MELAS mutations) were analyzed by RFLP methods as previously described (11) . wolframin exons were amplified with intronic primers (Table 2) . Amplified fragments were analyzed by SSCP using Hydrolink (AT Biochemical) gels at 20_C with and without glycerol. Staining was performed with VistraGreen and detection performed with a FluorImager (Molecular Dynamics). Variant bands were reamplified and used for direct sequencing with both the sense and antisense primer using a Taq DyeDeoxy Terminator Cycle sequencing kit (ABI). Sequences were determined with an Applied Biosystems 377 automated sequencer (accession nos Y18064, AJ 011971).
